Zavegepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura. CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways.
- Mechanism
- Curator reviewed · 4 references
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for the acute treatment of migraine. The pathophysiology of migraine has not been fully elucidated; however, specific vasoactive substances and neurotransmitters such as CGRP, neurokinin A, nitric oxide, and substance P may participate in the neurovascular and cortical spreading depression mechanisms. In acute migraine, the release of CGRP increases vasodilation and modulates neuronal excitability, which facilitates pain responses in structures for migraine pain transmission, such as the trigeminal system. Therefore, CGRP receptor antagonists such as zavegepant inhibit vasodilation mechanisms and desensitize neuronal circuits.
- Primary indication
- Zavegepant in a nasal spray form is indicated for the acute treatment of migraine with or without aura in adults.Curator reviewed · 1 structured indication
- Formula / weight
- C36H46N8O3 · 638.817 g/mol (avg)
- First approval
- United States, 2023
- Also known as
- Vazegepant
- Code names
- BHV-3500 · BMS-742413 · BMS-742413-01 · PF-07930207
- Brand names
Resolves to
JJVAPHYEOZSKJZ-JGCGQSQUSA-NSMILESCN1CCC(CC1)N1CCN(CC1)C(=O)[C@@H](CC1=CC2=C(NN=C2)C(C)=C1)NC(=O)N1CCC(CC1)C1=CC2=C(NC1=O)C=CC=C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Zavegepant, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account